Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.

Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?

Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.

Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

After Niagara the company faces three pivotal catalysts; none is a slam-dunk.

It’s back to school for biotech, with a packed conference schedule.

A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.